Margy Meislin

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

|

New York, N.Y., October 21, 2025 —  With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October 24-29, Chicago), the annual meeting of the American College of Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments and research.  As the … Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

|

The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from Genentech for the treatment of adults with active lupus nephritis in combination with standard of care. This is a major step forward for the entire lupus community, as it is the only anti-CD20 monoclonal antibody targeting an … Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Selected as Inaugural Strategic Collaborators with Vie Ventures to Advance Innovative Autoimmune Therapies   

|

The Lupus Research Alliance and clinical affiliate Lupus Therapeutics are proud to be selected as inaugural collaborators of the new life sciences investment firm, Vie Ventures.   Vie Ventures is focused on bridging venture capital and disease philanthropy. The organization is concentrating on advancing late-stage, breakthrough therapies for autoimmune diseases and other immune system disorders where … Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Selected as Inaugural Strategic Collaborators with Vie Ventures to Advance Innovative Autoimmune Therapies   

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

|
Breaking news: Gazyva for Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

|
Breaking News

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the … Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study